1.43 USD
+0.02
1.42%
At close Updated Mar 16, 4:00 PM EDT
1 day
1.42%
5 days
1.42%
1 month
11.72%
3 months
0%
6 months
-22.28%
Year to date
7.52%
1 year
-87%
5 years
-99.93%
10 years
-99.86%
 

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13

0
Funds holding %
of 8,079 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™